Insurers change breast screening rules
Several U.S. insurance companies have changed their guidelines for mammography screening in response to new recommendations from the National Cancer Institute and American Cancer Society that women ages 40 to 49 receive regular screening, according to
Several U.S. insurance companies have changed their guidelines for mammography screening in response to new recommendations from the National Cancer Institute and American Cancer Society that women ages 40 to 49 receive regular screening, according to Amnews, the newspaper of the American Medical Association. The NCI changed its recommendation in March to advocate screening women in the younger age group (SCAN 4/2/97).
Aetna U.S. Healthcare and Anthem Blue Cross/Blue Shield now say they will encourage and pay for screening for women in the younger age group, although individual health plans have some flexibility in implementing the policy. Both companies previously covered regular mammography screening starting at age 50.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
